Show simple item record

dc.contributor.authorWagner, Karen Dineen
dc.contributor.authorWeller, Elizbeth B.
dc.contributor.authorCarlson, Gabrielle A.
dc.contributor.authorSachs, Gary
dc.contributor.authorBiederman, Joseph
dc.contributor.authorFrazier, Jean A.
dc.contributor.authorWozniak, Patricia
dc.contributor.authorTracy, Katherine
dc.contributor.authorWeller, Ronald A.
dc.contributor.authorBowden, Charles
dc.date2022-08-11T08:10:27.000
dc.date.accessioned2022-08-23T17:09:36Z
dc.date.available2022-08-23T17:09:36Z
dc.date.issued2002-10-05
dc.date.submitted2011-02-10
dc.identifier.citationJ Am Acad Child Adolesc Psychiatry. 2002 Oct;41(10):1224-30. <a href="http://dx.doi.org/10.1097/00004583-200210000-00012">Link to article on publisher's site</a>
dc.identifier.issn0890-8567 (Linking)
dc.identifier.doi10.1097/00004583-200210000-00012
dc.identifier.pmid12364844
dc.identifier.urihttp://hdl.handle.net/20.500.14038/45861
dc.description.abstractOBJECTIVE: This study evaluated the safety and effectiveness of divalproex sodium (Depakote ) in the treatment of youths with bipolar disorder. METHOD: Forty bipolar disorder patients aged 7 to 19 years, with a manic, hypomanic, or mixed episode, enrolled in an open-label study of divalproex (2-8 weeks), followed by a double-blind, placebo-controlled period (8 weeks). RESULTS: Twenty-two subjects (61%) showed > or =50% improvement in Mania Rating Scale (MRS) scores during the open-label period. Significant ( <.001) improvements from baseline were seen for mean scores of all efficacy measures, including the MRS, Manic Syndrome Scale, Behavior and Ideation Scale, Brief Psychiatric Rating Scale, Clinical Global Impressions Severity scale, and Hamilton Rating Scale for Depression. Of the 23 subjects who discontinued the study during the open-label period, 6 (15%) discontinued for ineffectiveness, 6 (15%) for intolerance, 6 (15%) for noncompliance, and 6 (15%) for other reasons. Adverse events were generally mild or moderate in severity, with the most common being headache, nausea, vomiting, diarrhea, and somnolence. Laboratory data results were unremarkable. Too few subjects participated in the double-blind period for statistical analysis. CONCLUSION: This study provides preliminary support for the safety and effectiveness of divalproex in the treatment of bipolar disorder in youths.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=12364844&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1097/00004583-200210000-00012
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAntimanic Agents
dc.subjectBipolar Disorder
dc.subjectChild
dc.subjectFemale
dc.subjectHumans
dc.subjectLogistic Models
dc.subjectMale
dc.subjectValproic Acid
dc.subjectPsychiatry
dc.titleAn open-label trial of divalproex in children and adolescents with bipolar disorder
dc.typeJournal Article
dc.source.journaltitleJournal of the American Academy of Child and Adolescent Psychiatry
dc.source.volume41
dc.source.issue10
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/389
dc.identifier.contextkey1775321
html.description.abstract<p>OBJECTIVE: This study evaluated the safety and effectiveness of divalproex sodium (Depakote ) in the treatment of youths with bipolar disorder.</p> <p>METHOD: Forty bipolar disorder patients aged 7 to 19 years, with a manic, hypomanic, or mixed episode, enrolled in an open-label study of divalproex (2-8 weeks), followed by a double-blind, placebo-controlled period (8 weeks).</p> <p>RESULTS: Twenty-two subjects (61%) showed > or =50% improvement in Mania Rating Scale (MRS) scores during the open-label period. Significant ( <.001) improvements from baseline were seen for mean scores of all efficacy measures, including the MRS, Manic Syndrome Scale, Behavior and Ideation Scale, Brief Psychiatric Rating Scale, Clinical Global Impressions Severity scale, and Hamilton Rating Scale for Depression. Of the 23 subjects who discontinued the study during the open-label period, 6 (15%) discontinued for ineffectiveness, 6 (15%) for intolerance, 6 (15%) for noncompliance, and 6 (15%) for other reasons. Adverse events were generally mild or moderate in severity, with the most common being headache, nausea, vomiting, diarrhea, and somnolence. Laboratory data results were unremarkable. Too few subjects participated in the double-blind period for statistical analysis.</p> <p>CONCLUSION: This study provides preliminary support for the safety and effectiveness of divalproex in the treatment of bipolar disorder in youths.</p>
dc.identifier.submissionpathpsych_pp/389
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages1224-30


This item appears in the following Collection(s)

Show simple item record